Sunday, October 16, 2016 8:47:21 AM
Further, a coincidence when the rat lives more than 8 times longer? That is stretching it a bit --- they will do more testing to confirm, but it is highly unlikely that it is merely a coincidence.
The big question is if it only prolongs the inevitable or actually eliminated the problem permanently. Also, whether side-effects or the treatment itself is worse than the original condition - all things we don't know yet. But so far it appears very promising. Also, as always, rat experiments are one thing, but things don't always translate to humans 1:1. So far so good, but still very early on.
If anything, the 10% cut after the 18% gain is because of just how early things are with this AND that everyone is still waiting on HC to get trials underway and this info doesn't change that fact. Just another buying opportunity if you ask me - we might have to wait a bit, but one can accumulate quite a nice position under .30 here and long-term that is quite the bargain IMHO.
Following the charts is like driving a car forward while looking in the rear view mirror.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM